News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Prostate Cancer

Latest News

Prostate Cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

June 7th 2026

Aglatimagene Besadenovec Plus EBRT Improves Prostate Cancer-Specific DFS

By Kyle Doherty

Aglatimagene besadenovec plus ERBT displayed an accumulating benefit in high-risk prostate cancer after extended follow-up.

The top 5 OncLive TV videos of the week cover insights in breast cancer, ovarian cancer, prostate cancer, acute myeloid leukemia, and mantle cell lymphoma.

Five Under 5: Top Oncology Videos for the Week of 6/1/2026

By OncLive Staff

Prostate Cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

Extended Pelvic Lymph Node Dissection Improves MFS in High-Grade Prostate Cancer

By Kyle Doherty

Talazoparib Plus Enzalutamide in HRR-Altered mCSPC | Image Credit: © Dr_Microbe - stock.adobe.com

TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC

Lutetium Lu 177 Vipivotide Tetraxetan in mHSPC: ©Dr_Microbe - stock.adobe.com

Lutetium Lu 177 Vipivotide Tetraxetan Triplet Shows Consistent rPFS Benefit Across Disease Volume and mHSPC Status Subgroups

By OncLive Staff

Video Series

Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer

Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer

Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape

Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape

Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer

Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer

Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis

Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis

Treatment Selection in Metastatic and Castration Resistant Prostate Cancer Optimizing Outcomes and Preserving Patient Quality of Life

Treatment Selection in Metastatic and Castration Resistant Prostate Cancer Optimizing Outcomes and Preserving Patient Quality of Life

Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer

Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer

Optimizing Care of Patients With Advanced Prostate Cancer: Conclusion

Optimizing Care of Patients With Advanced Prostate Cancer: Conclusion

Clinical Case 4: Radiation Therapy

Clinical Case 4: Radiation Therapy

Clinical Case 3: Extensive Lymph Node Disease

Clinical Case 3: Extensive Lymph Node Disease

Clinical Case 2: Solitary Lymph Node

Clinical Case 2: Solitary Lymph Node

Latest Videos

Thomas J. Polascik, MD, Duke Cancer Institute

Dr Polascik on an AI-Driven Urine Volatile Compound Profiling Approach for Prostate Cancer Detection

Martin W. Schoen, MD, MPH

Dr Schoen on a Real-World Study of Enzalutamide vs Apalutamide in mCSPC

Fred Saad, MD, CQ, FRCS, FCAHS, Montreal Cancer Institute

Dr Saad on PSA End Points of the Phase 3 PSMAddition Study in PSMA+ mHSPC

Jason Hafron, MD

Dr Hafron on a Multidisciplinary Quality Initiative Designed to Mitigate the AEs of ADT in Prostate Cancer

Mark Garzotto, MD

Dr Garzotto on Aglatimagene Besadenovec Plus Valacyclovir and EBRT in Localized Prostate Cancer

Rana R. McKay, MD, UC San Diego

Dr McKay on Real-World QOL and Safety Outcomes With Relugolix in Advanced Prostate Cancer

Rana McKay, MD, UC San Diego

Dr McKay on the Design and Baseline Characteristics of the OPTYX Trial in Prostate Cancer

Rana R. McKay, MD, UC San Diego

Dr McKay on the Background of the Phase 4 OPTYX Trial in Advanced Prostate Cancer

Xiao Wei, MD, MAS, Dana-Farber Cancer Institute

Dr Wei on the FDA Approval of Pylarify TruVu for PSMA-PET Imaging in Prostate Cancer

David Wise, MD, NYU

Dr Wise on the Safety Profile of Pasritamig Plus Docetaxel in mCRPC

Shorts

Mark Garzotto, MD

Aglatimagene Besadenovec Emerges in Prostate Cancer

5 days ago

by

Mark Garzotto, MD

Murilo De Almeida Luz, MD, Mount Sinai

Discussing Findings From a Post Hoc Analysis of DAROL in Prostate Cancer

21 days ago

by

Murilo De Almeida Luz, MD

Fred Saad, MD

Unpacking the PSA End Points of PSMAddition in Prostate Cancer

21 days ago

by

Fred Saad, CQ, MD, FRCS, FCAHS

Herbert Lepor, MD, NYU Langone

Follow-Up After Focal Cryo-Ablation in Intermediate Favorable Risk Prostate Cancer

22 days ago

by

Herbert Lepor, MD

Jason Hafron, MD

Implementing a Multidisciplinary Quality Initiative in Prostate Cancer

23 days ago

by

Jason Hafron, MD

Mark Garzotto, MD

Aglatimagene Besadenovec Plus Valacyclovir and EBRT in Prostate Cancer

24 days ago

by

Mark Garzotto, MD

Jeff M. Michalski, MD, MBA, FACR, FASTRO, WashU Medicine

Tracking the Evolution of Radiopharmaceuticals in Prostate Cancer

a month ago

by

Jeff Michalski, MD, MBA, FASTRO

OncLive News Roundup for the Week of 4/26

OncLive News Roundup for the Week of 4/26

a month ago

by

Chris Ryan(+1 more)

Jeff M. Michalski, MD, MBA, FACR, FASTRO, WashU Medicine

Evaluating the Landscape of Radioligand Therapies in Prostate Cancer

2 months ago

by

Jeff Michalski, MD, MBA, FASTRO

Rana R. McKay, UC San Diego

Unpacking Real-World Use of Relugolix in Prostate Cancer

2 months ago

by

Rana R. McKay, MD

Podcasts

David Morris, MD, FACS, and Alan H. Bryce, MD

FDA Approval Insights: Rucaparib for BRCA Mutation–Associated mCRPC: With David Morris, MD, FACS; and Alan H. Bryce, MD

Samantha A. Armstrong, MD, hematologist/oncologist, assistant professor, clinical medicine, Indiana University Health; Karine Tawagi, MD, hematologist/oncologist, assistant professor, clinical medicine, the University of Illinois

ASCO GU 2026 Takeaways

Benjamin P. Levy, MD, clinical director, medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospital, associate professor, oncology, Johns Hopkins University School of Medicine; Scott T. Tagawa, MD, MS, FACP, FASCO, professor, medicine and urology, Weill Cornell Medicine, attending physician, NewYork-Presbyterian – Weill Cornell Medical Center

November 13, 2025

PSMA Theranostics, ctDNA Testing, and Combination Regimens in GU Oncology Spark Conversation at CFS: With Benjamin P. Levy, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Neal Shore, MD, FACS, medical director, Carolina Urologic Research Center

October 31, 2025

Ongoing ADT Use and Research Emphasizes the Importance of Shared Decision-Making in Prostate Cancer Care: With Neal Shore, MD, FACS

Neeraj Agarwal, MD

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Andrew J. Armstrong, MD, MSc

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Michael C. Haffner, MD, PhD

Haffner Highlights Treatment and Research Considerations for Basal Cell Carcinoma of the Prostate

Amar U. Kishan, MD

Kishan Discusses GI Toxicity Reduction With MRI-Guided SBRT in Prostate Cancer

Petrylak Provides Insight Into Testing, Multidisciplinary Management in Prostate and Bladder Cancer

August 22, 2022

Petrylak Provides Insight Into Testing, Multidisciplinary Management in Prostate and Bladder Cancer

FDA Approval Insights: Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer

August 15, 2022

FDA Approval Insights: Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer

CME Content

10th Annual Live Medical Crossfire®: Hematologic Malignancies

In-Person + Virtual Event

10th Annual Live Medical Crossfire®: Hematologic Malignancies

July 11-12, 2026

Iowa Oncology Society

Iowa Oncology Society

2 Sessions are Available!

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Nevada Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Nevada Oncology Society

Seth A. Wander, MD, PhD; Ruta D. Rao, MD

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Marla D. Lipsyc-Sharf, MD; Richard Zelkowitz, MD

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society

Seth A. Wander, MD, PhD; Kate Baxstrom, MD

Wyoming State Oncology Society

Wyoming State Oncology Society

2 Sessions are Available!

Kansas Society of Clinical Oncology

Kansas Society of Clinical Oncology

1 Session is Available!

North Carolina Oncology Association

North Carolina Oncology Association

2 Sessions are Available!

Live Tumor Board: Exploring Novel Targets and Breakthrough Treatment Strategies in Extrapulmonary Neuroendocrine Carcinomas

Live Tumor Board: Exploring Novel Targets and Breakthrough Treatment Strategies in Extrapulmonary Neuroendocrine Carcinomas

Aman Chauhan, MD, MBBS; Jonathan Strosberg, MD; Sylvia L. Asa, MD, PhD

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCR

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

William J. Gradishar, MD, FASCO, FACP; Rebecca Arend, MD, MSPH; Aaron Lisberg, MD; Ulka Vaishampayan, MD, FASCO

Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care

Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care

Benjamin P. Levy, MD; Sarah Goldberg, MD, MPH; Jacob Sands, MD; Helena Yu, MD

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Seth A. Wander, MD, PhD; Yang Liu, MD

Louisiana Oncology Society

Louisiana Oncology Society

2 Sessions are Available!

Missouri Oncology Society

Missouri Oncology Society

2 Sessions are Available!

New Mexico Society of Clinical Oncology

New Mexico Society of Clinical Oncology

2 Sessions are Available!

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

John H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MD

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Eileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPH

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MS

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Wisconsin Association of Hematology and Oncology

Wisconsin Association of Hematology and Oncology

1 Session is Available!

Indiana Oncology Society

Indiana Oncology Society

2 Sessions are Available!

Arkansas Association of Cancer Professionals

Arkansas Association of Cancer Professionals

1 Session is Available!

Rhode Island Oncology Society

Rhode Island Oncology Society

3 Sessions are Available!

Kentucky Society of Clinical Oncology

Kentucky Society of Clinical Oncology

2 Sessions are Available!

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Empire State Hematology & Oncology Society (New York)

Empire State Hematology & Oncology Society (New York)

3 Sessions are Available!

Minnesota Society of Clinical Oncology

Minnesota Society of Clinical Oncology

1 Session is Available!

South Carolina Oncology Society

South Carolina Oncology Society

2 Sessions are Available!

West Virginia Oncology Society

West Virginia Oncology Society

1 Session is Available!

Breaking Down the Rationale for Targeting TROP2 in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Establishing the Rationale for ADC and ICI Combinations in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MS

Cross-Disease Integration of Immunotherapy Innovations

Cross-Disease Integration of Immunotherapy Innovations

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Optimizing Treatment for Biliary Tract Cancers

Optimizing Treatment for Biliary Tract Cancers

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Tina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhD

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Yana G. Najjar, MD; Sapna Patel, MD

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Sandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHS

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

SriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRS

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

9th Annual School of Nursing Oncology™

9th Annual School of Nursing Oncology™

Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO; Beth Sandy, MSN, CRNP, FAPO; Lindsay Adkins, MSN, FNP-BC, BMTCN; Jeneth Aquino, DNP, FNP-BC; Casey Gormley, MSN, FNP-C, AOCNP; Heather J. Jackson, PhD, FNP-BC; Kelsey Martin, AG-ACNP-BC, AOCNP; Nerina T. McDonald, PA-C; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Faith A. Mutale, DNP, CRNP; Tiffany Richards, PhD, ANP-BC, AOCNP; Emily Skotte, DNP, MSN, ACNP-BC; Leslie Smith, DNP, RN, APRN-CNS, AOCNS, BMTCN; Saneese Stephen, PA-C, MPAS; Sara M. Tinsley-Vance, PhD, APRN, AOCN

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Charu Aggarwal, MD, MPH, FASCO; Zofia Piotrowska, MD, MHS

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Jacob Sands, MD; Anne Chiang, MD, PhD

More News

Perioperative Apalutamide Plus ADT in Prostate Cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

PROTEUS Data Support Perioperative Apalutamide Plus ADT as New SOC in High-Risk Localized Prostate Cancer

May 31st 2026

Perioperative apalutamide plus ADT improved metastasis-free survival and pathologic responses in high-risk localized prostate cancer.

Nicholas Zorko, MD, PhD

B7-H3 ADCs Show Promise Across Lung, Prostate, and Gynecologic Cancers

May 28th 2026

Nicholas Zorko, MD, PhD, discusses B7-H3 targeting in lung, GU, and gynecologic malignancies.

2026 AUA Annual Meeting: ©Sebastian Kaulitzki - stock.adobe.com

Experts Recap the Most Notable Data in GU Cancers Presented During the 2026 AUA Annual Meeting

May 27th 2026

OncLive spoke with experts in the field of GU oncology to gain their insights on the most notable presentations from the 2026 AUA Annual Meeting.

The top 5 OncLive TV videos of the week cover insights in breast cancer, ovarian cancer, prostate cancer, acute myeloid leukemia, and mantle cell lymphoma.

Five Under 5: Top Oncology Videos for the Week of 5/17

ByOncLive Staff

May 24th 2026

The top 5 OncLive TV videos of the week cover insights in breast cancer, ovarian cancer, prostate cancer, acute myeloid leukemia, and mantle cell lymphoma.

BRCA+ mCRPC | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

Enzalutamide Plus Radium-223 Demonstrates Delayed but Substantial Long-Term Survival Benefit in mCRPC

ByOncLive Staff

May 18th 2026

Enzalutamide plus radium-223 demonstrated no early survival advantage but an 80% death risk reduction for long-term survivors in mCRPC at over 60 months.

BRCA+ mCRPC | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

TRITON3 Update Solidifies Manageable Safety Profile of Rucaparib in BRCA+ mCRPC

ByJason Broderick

May 18th 2026

Rucaparib showed a manageable and consistent safety profile in patients with BRCA-mutated prostate cancer.

BCG-Naive High-Risk NMIBC | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

Durvalumab Plus BCG Demonstrates Manageable Safety Profile in BCG-Naive High-Risk NMIBC

ByOncLive Staff

May 18th 2026

No new safety signals were identified, and imAEs were predominantly low-grade and consistent with the known durvalumab safety profile.

mHSPC | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

Lutetium Lu 177 Vipivotide Tetraxetan Plus ADT/ARPI Improves Frequency, Depth of PSA Responses in PSMA+ mHSPC

ByOncLive Staff

May 17th 2026

Adding lutetium Lu 177 vipivotide tetraxetan to ADT and ARPI deepened PSA responses and reduced the risk of PSA progression by 58% in patients with mHSPC.

TALAPRO-2 Post Hoc Analysis in mCRPC | Image Credit: © pikovit - stock.adobe.com

TALAPRO-2 Analysis Shows Moderate-to-Strong rPFS Correlation With OS in First-Line mCRPC

ByOncLive Staff

May 17th 2026

Talazoparib plus enzalutamide data show rPFS correlates moderate-to-strongly with OS in first-line mCRPC across biomarker-defined subgroups.

Biochemically recurrent prostate cancer | Image Credit: ©Sebastian Kaulitzki - stock.adobe.com

Enzalutamide Plus Leuprolide Yields Prolonged Treatment Suspension in Biochemically Recurrent Prostate Cancer

ByOncLive Staff

May 17th 2026

Enzalutamide plus leuprolide produced a median treatment suspension of 17 months vs 11.5 months with leuprolide alone in biochemically recurrent prostate cancer.

mHSPC | Image Credit: © pikovit - stock.adobe.com

Darolutamide Plus ADT Yields Significant OS Benefit in mHSPC

ByJason Broderick

May 15th 2026

Darolutamide plus ADT demonstrated a 50% reduction in the risk of death in metastatic hormone-sensitive prostate cancer.

AUA 2026 | Image Credit: © Adin - stock.adobe.com

IO in NMIBC, Radioligand Therapy in mHSPC Highlight Key Presentations to Watch at AUA 2026

May 14th 2026

Ahead of the 2026 AUA Annual Meeting, GU cancer experts highlighted the abstracts that they are anticipating the most.

Sagar A. Patel, MD | Image © pikovit - stock.adobe.com

REVELUTION-2 Trial Is Evaluating Cardiovascular Risk With Relugolix Plus Abiraterone Acetate in High-Risk Prostate Cancer

May 14th 2026

Sagar A. Patel, MD, discusses the REVELUTION-2 trial evaluating cardiovascular safety with hormone therapy in prostate cancer.

AUA and SUO Amend Advanced Prostate Cancer Guideline: ©Dr_Microbe - stock.adobe.com

AUA and SUO Amend Advanced Prostate Cancer Guideline

May 12th 2026

The AUA and SUO released the 2026 amendment to the Advanced Prostate Cancer Guideline.

[177Lu]Lu-D-Dan-Phe-PSMA in mCRPC: ©pikovit - stock.adobe.com

[177Lu]Lu-D-Dan-Phe-PSMA Demonstrates Manageable Safety and Early Efficacy mCRPC

May 12th 2026

[177Lu]Lu-D-Dan-Phe-PSMA showed early signals of safety and activity in mCRPC.

Prostate Cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

Treatment Intensification Gains Momentum in mCSPC Management

May 11th 2026

During a recent OncLive Peer Exchange, prostate cancer experts discussed the evolving role of treatment intensification in mCSPC.

Grade Group 5 Prostate Canc © pikovit - stock.adobe.com

Nivolumab Plus SOC Therapy Shows Encouraging Disease Control in Grade Group 5 Prostate Cancer

May 10th 2026

The regimen produced a 2-year freedom from biochemical recurrence rate of 90.3% in grade group 5 prostate cancer.

The FDA cleared vepdegestrant in ER+ breast cancer with ESR1 mutations, ODAC voted on key questions in breast and prostate cancer, and more.

The OncFive: Top Oncology Articles for the Week of 4/26

ByOncLive Staff

May 2nd 2026

The FDA cleared vepdegestrant in ER+ breast cancer with ESR1 mutations, ODAC voted on key questions in breast and prostate cancer, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

OncLive Weekly News Quiz (5/1/2026): Are You Caught Up on 2 FDA ODAC Votes in Prostate and Breast Cancer?

ByOncLive Staff

May 1st 2026

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

FDA

FDA ODAC Votes in Favor of Risk:Benefit Profile of Capivasertib Plus Abiraterone in PTEN-Deficient mHSPC

April 30th 2026

The FDA ODAC voted for the use of capivasertib plus abiraterone in PTEN-deficient mHSPC.

mHSPC | Image Credit: © pikovit - stock.adobe.com

FDA ODAC: Reviewing Data for Capivasertib Plus Abiraterone in PTEN-Deficient mHSPC

April 30th 2026

Capivasertib plus abiraterone produced superior efficacy outcomes vs abiraterone alone in PTEN-deficient mHSPC.

Prostate Cancer | Image Credit: © Dr_Microbe - stock.adobe.com

FDA ODAC Live Updates: Committee Weighs Data for Capivasertib Plus Abiraterone in PTEN-Deficient mHSPC

Published: April 29th 2026 | Updated: April 30th 2026

The April 30, 2026, FDA ODAC meeting will focus on data from CAPItello-281 for capivasertib plus abiraterone in PTEN-deficient mHSPC.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, chronic lymphocytic leukemia, salivary gland cancer, cholangiocarcinoma, and prostate cancer.

Five Under 5: Top Oncology Videos for the Week of 4/5

ByOncLive Staff

April 12th 2026

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, chronic lymphocytic leukemia, salivary gland cancer, cholangiocarcinoma, and prostate cancer.

Early-Stage Prostate Cancer | Image Credit: © pikovit - stock.adobe.com

Pasritamig Plus Docetaxel Produces Strong Efficacy and Safety Data in mCRPC, Moves Into Phase 3 Study

April 6th 2026

David R. Wise, MD, PhD, discusses data from a phase 1b study of pasritamig plus docetaxel in mCRPC.

Image Credit: © catalin - stock.adobe.com

Revisit Every OncLive On Air Episode From March 2026

ByAshling Wahner

April 6th 2026

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in March 2026.

Trending on OncLive

Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer

Hematologists Highlight Top Data From ASCO 2026

INDEPENDENCE, Type II JAK Inhibitor Data Highlight Key MPN and AML Data Arriving at EHA 2026

Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma

Aglatimagene Besadenovec Plus EBRT Improves Prostate Cancer-Specific DFS